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ABSTRACT 
Objective: This investigation demonstrates a stability-indicating and reliable “high-performance liquid chromatography” method to simultaneously 
quantify tricholine citrate (TEC) and cyproheptadine (CRH) in the syrup form and bulk form.  
Methods: Successful separation was accomplished using C18 “Agilent column (250 mm × 4.6 mm, 5 μm)” with isocratic type of elution using mobile 
phase containing 0.1 M NaH2PO4
Results: TEC and CRH peaks were eluted with fine resolution at retention times 1.837 min and 2.936 min, respectively. In the 137.5-412.5 μg/ml 
and 1-3 μg/ml concentration ranges for TEC and CRH, the calibration graphs were linear, with regression coefficients of 0.9999 and 0.9998, 
respectively. The suggested "high-performance liquid chromatography" approach has been shown as sensitive, precise, robust, accurate, specific 
and stability indicating through the resolution of TEC and CRH from its degradation-based compounds.  
 buffer and acetonitrile at 55% volume and 45% volume ratio, respectively with 1.0 ml/min flow rate. The 
wavelength sensor was attuned at 263 nm to quantify TEC and CRH.  
Conclusion: The established high-performance liquid chromatography technique was effectively extended to the evaluation of TEC and CRH in the 
combined syrup form and the test results appeared satisfactory. 
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INTRODUCTION 
Tricholine Citrate (TEC) is recommended in the adults to treat and 
control hepatic and pancreatic disorders [1-3]. In hepatic cells, TEC 
confers lipotropic behaviour. TEC can also alleviate asthma 
complications and reduce the leukotriene pathway's pro-
inflammatory and also inflammatory mediators. Chemically, TEC is 
described as 2-hydroxy-N,N,N-trimethylethanaminium 2-
hydroxyproline-1,2,3-tricarboxylate (fig. 1). Cyproheptadine (CRH) 
relieves irritated, red, itchy, watery eyes, sneezing, and runny nose 
triggered by irritants present in air, allergies and hay fever [4-6]. 
CRH can often be used to relieve itching of allergic skin conditions 
and also to treat rashes, including rashes due to cold temperature 
stimulation and skin rubbing. CRH is in a category of medicines 
recognized as antihistamines. CRH functions by suppressing the 
activity of histamine, a material that triggers body’s allergic 
reactions. Chemically CRH is described as 4-(5H-
Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine (fig. 1). 
 
 
Fig. 1: Structures of drugs 
 
Combination therapies become part of the standardized testing of all 
drugs and the treatment of all diseases [7-10]. A combination 
treatment is a therapeutic approach in which the patient is given 
more than one treatment. Cases of combination therapies include 
treatments that involve the treatment with many different 
medications, each comprising a specific drug, or the single 
medication containing several drugs.  
The combination of TEC and CRH is available as a syrup formulation 
[11-15]. The TEC and CRH combination therapy increases appetite, 
offers the efficient hepato-protective operation, guarantees weight 
gaining and boosts protein synthesis. Combination treatment with 
TEC and CRH is prescribed for the hepatobiliary conditions linked 
with anorexia, leading to weight reduction [16]. To the maximum of 
our awareness, no procedures for measuring the combination of TEC 
and CRH in syrup preparations have been established yet. This 
paper proposes a novel sensitive stability-indicating HPLC 
procedure for the assessment of TEC and CRH combination. The 
process proposed enables the rapid assessment of the mixture of 
TEC and CRH in bulk drugs and syrup preparations without sample 
pretreatment with high precision and specificity, and with no 
excipient intervention. 
MATERIALS AND METHODS 
Chemicals 
NaH2PO4, HCl, NaOH, H2O2 and orthophosphoric acid were acquired 
from “Sd Fine Chemicals Ltd, India”. Acetonitrile was acquired from 
“Merck India Ltd, India”. TEC and CRH bulk samples were gifted 
from “Rainbow pharma training labs, India”. Cypro T formulation 
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syrup from “Nexkem Pharmaceutical, India” with labelled claim of 2 
mg CRH and 275 mg TEC was utilized.  
Instrument and evaluation conditions 
Separations and analyses of TEC and CRH were accomplished using 
Waters chromatograph (2695) system furnished with Waters 
photodiode (2998) detector. The column employed was “Agilent C18 
(250 mm × 4.6 mm and 5 µm)” with room temperature. Mobile 
phase employed was a combination of 0.1 M NaH2PO4
Standard TEC and CRH solution 
 buffer and 
acetonitrile at 55% volume and 45% volume ratio, respectively with 
1.0 ml/min flow rate. The buffer’s pH was tuned at 4.0 value with 
0.1% orthophosphoric acid. The mobile phase was degassed and 
filtered before utilization through degasser and 0.45 μm membrane 
filters, respectively. The peak area intensity of TEC and CRH was 
measured at 263 nm with the injection size volume of 10 µl. 
Standard TEC and CRH solution containing 2750 μg/ml (TEC) and 20 
μg/ml (CRH) was prepared by dissolving 275 mg of TEC and 2 mg of 
CRH in 100 ml of mobile phase solvent blend. The standard TEC and 
CRH solution were diluted employing mobile phase solvent blend 
further as needed.  
Procedures 
Calibration graphs of TEC and CRH  
Accurately assessed aliquot parts of the standard TEC and CRH were 
moved to a set of 10 ml volumetric bottles such that the ultimate 
concentrations were between 137.5-412.5 μg/ml (TEC) and 1-3 
μg/ml (CRH). The solutions are finished to volume employing mobile 
phase solvent blend and blended well. Samples of 10 μl volume were 
infused and eluted under optimal chromatographic constraints with 
the mobile phase solvent blend. The analyte peak areas against the 
ultimate drug concentrations were plotted. The related regression 
equations for TEC and CRH were alternatively derived. 
Analysis of TEC and CRH in the Cypro T formulation syrup 
A measured volume (5 ml) of syrup equivalent to 2 mg CRH and 275 
mg TEC was moved to 100 ml volumetric bottle, about 75 ml of 
mobile phase solvent blend was included and sonicated 30 min to 
dissolve TEC and CRH. The solution then was mobile phase-diluted 
to volume, blended and filtered. Aliquot consisting of concentration 
2 μg/ml of CRH and 275 μg/ml of TEC was moved to a 10 ml 
volumetric bottle. The process described under “Calibration graphs 
of TEC and CRH” was executed. The nominal contents of TEC and 
CRH in Cypro T formulation syrup were evaluated either from 
related calibration graph or from related regression equation. 
Procedures for TEC and CRH stability studies 
In compliance with ICH recommendations, the stability studies on 
Cypro T formulation solution were done [17].  
Degradation using alkaline 
Volume (10 ml) of Cypro T formulation solution containing 2750 
μg/ml (TEC) and 20 μg/ml (CRH) was moved to 100 ml volumetric 
bottle; 10 ml aliquot part of 0.1 N NaOH solution was included. The 
solution stayed sonicated 30 min at room temperature. After 
specified 30 min time, the contents of volumetric bottle were cooled, 
neutralized using 0.1N HCl. The solution then was mobile phase-
diluted to volume, blended and filtered. The process described under 
“Calibration graphs of TEC and CRH” was executed. The assay and 
degradation percentage of TEC and CRH were evaluated.  
Degradation using acid 
Volume (10 ml) of Cypro T formulation solution containing 2750 
μg/ml (TEC) and 20 μg/ml (CRH) was moved to 100 ml volumetric 
bottle; 10 ml aliquot part of 0.1 N HCl solution was included. The 
solution stayed sonicated 30 min at room temperature. After 
specified 30 min time, the contents of volumetric bottle were cooled, 
neutralized using 0.1N NaOH. The solution then was mobile phase-
diluted to volume, blended and filtered. The process mentioned 
under "TEC and CRH calibration graphs" has been implemented. TEC 
and CRH were tested for the assay and degradation percentage. 
Degradation using peroxide 
Volume (10 ml) of Cypro T formulation solution containing 2750 
μg/ml (TEC) and 20 μg/ml (CRH) was moved to 100 ml volumetric 
bottle; 10 ml aliquot part of 30% peroxide solution was included. 
The solution stayed sonicated 30 min at room temperature. After 
specified 30 min time, the solution then was mobile phase-diluted to 
volume, blended and filtered. The process described under 
“Calibration graphs of TEC and CRH” was executed. The assay and 
degradation percentage of TEC and CRH were evaluated.  
Degradation using sun light 
Volume (10 ml) of Cypro T formulation solution containing 2750 
μg/ml (TEC) and 20 μg/ml (CRH) was moved to 100 ml volumetric 
bottle. The bottle with Cypro T formulation solution was lay open to 
sun light for a time of 6 hr. After specified 6 hr time, the solution 
then was mobile phase-diluted to volume, blended and filtered. The 
process described under “Calibration graphs of TEC and CRH” was 
executed and followed by evaluation of assay and degradation 
percentage of TEC and CRH.  
Degradation using dry heat 
Volume (10 ml) of Cypro T formulation solution containing 2750 
μg/ml (TEC) and 20 μg/ml (CRH) was moved to 100 ml volumetric 
bottle. The bottle with Cypro T formulation solution was wide-open 
to 60 °C in oven for a time of 30 min. After specified 30 min time, the 
solution then was mobile phase-diluted to volume, blended and 
filtered. The assay and degradation percentage of TEC and CRH were 
evaluated employing process explained under “Calibration graphs of 
TEC and CRH”.  
RESULTS 
Validation of procedure 
In acquiescence with ICH recommendations, the validity parameters 
were established [18]. 
Linearity 
During this work, the linearity of area response was checked for 
both TEC and CRH. Chromatographed solutions with concentrations 
of 137.5-412.5 μg/ml for TEC and 1-3 μg/ml for CRH given linear 
peak response areas. The regression line equation, regression 
coefficient and TEC and CRH calibration curves are shown in fig. 2. 
Limits of quantification (Lq) and detection (Ld) 
Both Lq and Ld were measured utilizing a signal-to-noise 
methodology. Lq and Ld were defined as the TEC an CRH 
concentration levels that ensuing a peak height of 10 times and 3 
times, respectively the baseline noise. The Ld and Lq were found to 
be 0.124 μg/ml and 0.413 μg/ml, respectively, for TEC and 0.0023 
μg/ml and 0.0078 μg/ml, respectively, for CRH.  
Accuracy and precision 
The accuracy and precision measurements were assessed using 
measurements of TEC and CRH solution (2 µg/ml and 275 µg/ml) 
repeated six times within the day. The precision was validated by 
the RSD measurements of the TEC and CRH peak areas, while the 
accuracy was validated by the TEC and CRH percentage content 
assays (table 1). 
Recovery 
The recovery was determined by assay of TEC and CRH in spiked 
Cypro T samples according to proposed method. Three diverse 
quantities (50% quantity degree, 100% quantity degree and 150% 
quantity degree) of TEC and CRH standards were put into Cypro T 
samples. The recovered values of TEC and CRH were presented in 
table 2. 
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Fig. 2: TEC and CRH linearity curves 
 
Table 1: Precision and accuracy measurements for TEC and CRH 
Sample No. Precision Accuracy 
TEC area CRH area TEC % assay CRH % assay 
1 2581692 1673134 99.48 100.60 
2 2586089 1673918 99.65 100.65 
3 2610132 1680554 100.58 101.05 
4 2599406 1661186 100.17 99.88 
5 2595038 1664656 100.00 100.09 
6 2587896 1680666 99.72 101.05 
Avg. 2593375.50 1672352.33 99.93 100.55 
S. D 10387.8131 8041.9805 0.4025 0.4843 
R. S. D 0.4006 0.4809 0.4027 0.4817 
Avg.–mean of six measurements; SD–Deviation of value for six measurements; RSD–Percentage deviation 
 
Table 2: Recoveries of TEC and CRH 
Spiked degree (%) Quantity added (µg/ml) Quantity quantified* (µg/ml) Quantity recovered* (%) SD RSD 
50 136.125 134.90 99.10 0.4912 0.496 
100 272.2 271.88 99.86 0.1815 0.182 
150 408.375 408.88 100.12 0.0702 0.070 
50 0.99 0.99 100.42 0.0656 0.065 
100 1.98 1.97 99.53 0.3932 0.395 
150 2.97 2.96 99.71 0.1015 0.102 
*mean of three measurements; SD–Deviation of value for three measurements; RSD–Percentage deviation 
 
Robustness 
The robustness was measured using peak area measurements of TEC 
and CRH solution (2 µg/ml and 275 µg/ml) with considerably changed 
parameters in HPLC assay operating conditions. The changed 
parameters and peak areas obtained were presented in table 3. 
Selectivity 
To prove selectivity, a comparison of blank (mobile phase solvent 
blend), TEC and CRH solution (2 µg/ml and 275 µg/ml) and Cypro T 
sample (2 µg/ml and 275 µg/ml) chromatograms were made. The 
respective chromatograms were given away in fig. 3. 
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Peak area SD RSD Peak area SD RSD 
Acetonitrile volume 
(%) 
40 2598351 40645.7451 1.585 1682281 30050.9462 1.816 
45 2576531 1659686 
50 2519624 1622752 
Flow rate (ml/min) 0.9 2524231 42473.4756 1.653 1620685 31160.0151 1.884 
1.0 2576531 1659686 
1.1 2608351 1682281 
pH 3.8 2573576 2122.9900 0.082 1653039 3565.5242 0.215 
4.0 2576531 1659686 
4.2 2572413 1654126 
Wavelength 
(nm) 
261 2503577 36537.1568 1.439 1685964 31122.2638 1.879 
263 2576531 1659686 
265 2536424 1623959 
Temperature 
( °C) 
23 2539624 29307.7494 1.140 1632752 23092.1729 1.394 
25 2576531 1659686 
27 2597514 1678710 
SD–Deviation of value for three peak area measurements; RSD–Percentage deviation 
 
 
Fig. 3: Obtained chromatograms for (I) Cypro T sample (II) TEC an CRH solution (III) Blank 
 
Degradation study and specificity 
These investigations have been completed to explicate the intrinsic 
stability capabilities of TEC and CRH in combination under distinct 
situations of forced degradation described earlier. By using 0.1 N HCl, 
30% peroxide and dry heat, TEC percent recovery was decreased 
about 11.69%, 6.74% and 7.32%, respectively while CRH percent 
recovery was decreased about 8.42%, 4.97% and 6.52%, respectively. 
The chromatograms corresponding to TEC and CRH in 0.1N HCl, 30% 
peroxide and dry heat degradation were shown in fig. 4. I, 4. II and 4. 
III. In sunlight and 0.1 N NaOH conditions, TRH percent recovery was 
decreased about 9.08% and 5.36%, respectively and CRH was 
decreased by about 10.94% and 7.77%, respectively. The 
chromatograms corresponding to TEC and CRH in sunlight and 0.1 N 
NaOH degradation conditions were displayed in fig. 4. IV and 4. V. The 
additional peaks generated, in the course of 0.1 N HCl, 30% peroxide, 
dry heat, sunlight and 0.1 N NaOH conditions applied, resolved finely 
from the TEC and CRH peaks (fig. 4. I to 4. V). 
System suitability  
The system suitability measurements were assessed using 
measurements of TEC and CRH solution (2 µg/ml and 275 µg/ml) 
repeated five times. The system suitability was validated by 
measurements of plate counts, tailing symmetry, resolution, 
retention time and peak areas for the TEC and CRH peak (table 4). 
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Fig. 4: Obtained chromatograms for degradation with (I) 0.1N HCl (II) 30% peroxide (III) Dr heat (IV) Sun light (V) 0.1N NaOH 
 
Table 4: System suitability for assay of TEC and CRH 
Statistical data Retention period (min) Area Resolution Plate count Tailing 
TEC 
Avg. 1.837 2582140 - 6173 1.488 
SD 0.0011 8718.8306 - 125.6523 0.0130 
RSD 0.060 0.338 - 2.036 0.876 
 CRH 
Avg. 2.936 1656492 8.560 5625 1.196 
SD 0.0020 5194.4251 0.0361 39.4614 0.0089 
RSD 0.068 0.314 0.421 0.702 0.748 
Avg.–mean of five measurements; SD–Deviation of value for five measurements; RSD–Percentage deviation 
 
DISCUSSION 
To quantify CRH methods like spectrofluorimetry (by Belal et al.,) [19], 
UV spectrophotometry (by Wagh et al.,) [20], colorimetry (by Sayanna et 
al.,) [21], HPLC (by Maham et al., Sadhana et al., Mina et al., El-Din et al.,) 
[22-25] and LC-MS (Feás et al.,) [26] were reported. To quantity TEC no 
reports were found. Similarly, no procedures for measuring the 
combination of TEC and CRH in syrup preparations have been 
established yet. This paper proposes a novel sensitive stability-indicating 
HPLC procedure for the assessment of TEC and CRH combination. 
At the time of developmental trials, different C18 columns like YMC, 
Xterra, Waters and Agilent were investigated. The YMC and Xterra 
have dimensions of 150 mm length, 4.6 mm identification and 5 µm 
particle size. The Waters and Agilent have dimensions of 250 mm 
length, 4.6 mm identification and 5 µm particle size. As a mobile 
phase solvent blend, various solvent blends of different proportions 
have been checked. They include 0.1M K2HPO4: methanol, 0.1M 
Na2HPO4: acetonitrile and 0.1M NaH2PO4: acetonitrile. Resolution 
of TEC and CRH peaks was acceptable with C18 Aligent column at 
ambient temperature. 0.1M NaH2PO4 with 4 pH value and 
acetonitrile at the proportion of 55% volume and 45% volume [23], 
respectively, were optimized for the finest TEC and CRH peak shape 
and less retention time [23-26] for this proposed chromatographic 
process. To rapidly separate TEC and CRH, an isocratic elution mode 
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with 1.0 ml/min flow speed was preferred. At 263 nm, the response 
of the TEC and CRH was greater. Therefore, 263 nm was deemed an 
appropriate wavelength for TEC and CRH quantification. 
In part due to linear values, the linearity of calibration displays for 
TEC and CRH was verified by the large regression coefficient (R2
The percentile degradation specified that the TEC is really sensitive 
than CRH to 0.1 N HCl, 30% peroxide and dry heat degradation 
conditions executed. The stability of TRH is less than that of CRH under 
the sunlight and 0.1 N NaOH degradation conditions executed as the 
percent recovery of TRH was less than CRH. Complete resolution of 
TEC and CRH peaks from its degradation-based compounds with no 
seeming shoulders confirmed the stability indicating feature and 
specificity of the suggested HPLC approach [17, 29-31].  
) 
values for the TEC and CRH [18, 27, 28]. The Ld values and Lq values 
of TEC and CRH met the sensitivity prerequisite for quantifiable 
analysis of TEC and CRH [19-21, 25-28]. The RSD measurements and 
percentage content assays of TEC and CRH confirmed the good 
preciseness and accurateness, respectively, of HPLC method 
proposed [19-26]. The recoveries of TEC and CRH validated the 
accuracy and selectivity of HPLC method proposed [18, 27, 
28]. When modifications to the robustness analysis were made, no 
major differences were noted. The robustness of the suggested HPLC 
approach is thus proven [18, 27,28]. 
Blank chromatogram showed no any peaks at retention times of TEC 
and CRH. While peak retention times for TEC and CRH was almost 
similar in the Cypro T sample chromatogram and TEC and CRH 
solution chromatogram. Thus, suggested HPLC approach selectivity 
was verified [18-26]. The system suitability measurements like plate 
counts, tailing symmetry, resolution, retention time and peak areas 
for the TEC and CRH peak fall within the ICH prescribed criterion, 
indicating appropriateness of HPLC instrumentation for assay of TEC 
and CRH combination by suggested approach [18, 27, 28].  
CONCLUSION 
A “high-performance liquid chromatography” process for 
determining the combination of TEC and CRH in the syrup form and 
pure form has been described in the established method. The 
present “high-performance liquid chromatography” process is 
exemplified by its speed, ease and relatively inexpensive. The 
successful validity criteria of the proposed approach permit its use 
in laboratories for quality control. 
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